Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2009 1
2011 1
2012 1
2013 1
2014 1
2018 3
2019 9
2020 7
2021 12
2022 9
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Results by year

Filters applied: . Clear all
Page 1
Expression of DNA Repair Genes in Ewing Sarcoma.
Kyriazoglou A, Moutafi M, Zografos E, Konteles V, Sofianidis G, Mahaira L, Papakosta A, Tourkantoni N, Patereli A, Stefanaki K, Tzotzola V, Mpaka M, Polychronopoulou S, Dimitriadis E, Kattamis A. Kyriazoglou A, et al. Cancer Diagn Progn. 2024 May 3;4(3):231-238. doi: 10.21873/cdp.10313. eCollection 2024 May-Jun. Cancer Diagn Progn. 2024. PMID: 38707718 Free PMC article. Review.
Next-generation sequencing (NGS) profiling of matched tumor and circulating tumor DNA (ctDNA) in head and neck squamous cell carcinoma (HNSCC).
Economopoulou P, Spathis A, Kotsantis I, Maratou E, Anastasiou M, Moutafi MK, Kirkasiadou M, Pantazopoulos A, Giannakakou M, Edelstein DL, Sloane H, Fredebohm J, Jones FS, Kyriazoglou A, Gavrielatou N, Foukas P, Panayiotides I, Psyrri A. Economopoulou P, et al. Among authors: kyriazoglou a. Oral Oncol. 2023 Apr;139:106358. doi: 10.1016/j.oraloncology.2023.106358. Epub 2023 Mar 3. Oral Oncol. 2023. PMID: 36871349
Superficial soft tissue sarcomas: 10‑year survival outcomes.
Tolia M, Gkantaifi A, Hayward L, Gupta G, Kyriazoglou A, Mauri D, Nixon I. Tolia M, et al. Among authors: kyriazoglou a. Oncol Lett. 2023 Jan 27;25(3):96. doi: 10.3892/ol.2023.13682. eCollection 2023 Mar. Oncol Lett. 2023. PMID: 36817037 Free PMC article.
Clear cell sarcoma: state-of-the art and perspectives.
Wetterwald L, Riggi N, Kyriazoglou A, Dei Tos G, Dei Tos A, Digklia A. Wetterwald L, et al. Among authors: kyriazoglou a. Expert Rev Anticancer Ther. 2023 Mar;23(3):235-242. doi: 10.1080/14737140.2023.2183846. Epub 2023 Feb 27. Expert Rev Anticancer Ther. 2023. PMID: 36811446 Review.
Outcomes from treatment of metastatic renal-cell carcinoma following failure of first-line anti-VEGF/VEGFR therapy: real-life evidence on the change of the treatment paradigm.
Bamias A, Zakopoulou R, Tzannis K, Sakellakis M, Koutsoukos K, Kyriazoglou A, Panagiotou A, Armylagos S, Rokas K, Gotzias D, Boulouta A, Bozionelou V, Stravodimos K, Varkarakis I, Mavroudis D, Dimopoulos MA. Bamias A, et al. Among authors: kyriazoglou a. Anticancer Drugs. 2023 Mar 1;34(3):413-421. doi: 10.1097/CAD.0000000000001420. Epub 2022 Nov 16. Anticancer Drugs. 2023. PMID: 36730619 Clinical Trial.
Myxoid spindle cell sarcoma with ETV6-NTRK3 fusion.
Kyriazoglou A, Dimitriadis E, Mahaira L, Kotsantis J, Kouloulias V, Kontogeorgakos V, Psyrri A, Agrogiannis G. Kyriazoglou A, et al. Cancer Genet. 2022 Nov;268-269:93-96. doi: 10.1016/j.cancergen.2022.09.012. Epub 2022 Oct 2. Cancer Genet. 2022. PMID: 36274330
Tyrosine kinase inhibitors in sarcoma treatment.
Kyriazoglou A, Gkaralea LE, Kotsantis I, Anastasiou M, Pantazopoulos A, Prevezanou M, Chatzidakis I, Kavourakis G, Economopoulou P, Nixon IF, Psyrri A. Kyriazoglou A, et al. Oncol Lett. 2022 Jun;23(6):183. doi: 10.3892/ol.2022.13303. Epub 2022 Apr 21. Oncol Lett. 2022. PMID: 35527786 Free PMC article. Review.
46 results